Disease column
Condition-by-condition briefings from Lexaid (其乐无忧): how treatment options in China work, who may be considered, and what to confirm with the receiving hospital.
Articles
AAV Gene Therapy for Hemophilia A
A one-time AAV infusion delivers a working factor VIII gene into liver cells. It does not repair the inherited F8 gene, expression can fade, and factor replacement must not be stopped without a hematologist.
2026-10-29
Autocrine PD-1 Antibody, Mesothelin-Targeted CAR-T for Malignant Mesothelioma
A patient’s own T cells are engineered to recognize mesothelin and secrete a PD-1 antibody inside the tumor. Only mesothelin-positive disease is in scope. CRS and ICANS remain real risks. This is not a marketed cure.
2026-10-29
Non-Gene-Modified DC Vaccine for EBV-Related Blood Cancers
Autologous dendritic cells are loaded with EBV antigen and given back in repeated doses. The DCs are not gene-edited. This is not the RMB 16,000 anti-EBV DC product or the EBV mRNA vaccine on the same Lecheng list.
2026-10-29
Autologous Dendritic-Cell Therapy for Pancreatic and Colorectal Cancer
A patient’s monocytes are matured into dendritic cells, loaded with tumor antigen, and reinfused. The Lecheng catalog lists 3 sessions for colorectal cancer and 5 for pancreatic cancer. It does not replace standard cancer treatment.
2026-10-29
Tumor-Infiltrating Lymphocyte (TIL) Therapy for Advanced Solid Tumors
TILs are T cells taken from the tumor itself, expanded in a GMP lab, and infused after lymphodepleting chemotherapy. Strongest experience is in melanoma. Viable tumor tissue is mandatory, manufacturing can fail, and this is later-line care—not a cure.
2026-10-27
Gene-Modified Autologous Hematopoietic Stem Cells for Transfusion-Dependent Beta-Thalassemia
A patient’s own blood-forming stem cells are genetically modified and infused back, avoiding a donor and GVHD. Not everyone stops transfusions. Do not stop transfusion or iron chelation without a hematologist.
2026-10-27